Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data

Patients with type 2 diabetes mellitus (T2DM) are at high risk for cardiovascular (CV) disease; however, conclusive evidence that glycemic control leads to improved cardiovascular outcomes is lacking. Saxagliptin is a potent, selective dipeptidyl peptidase-4 inhibitor approved as an adjunct to diet...

Descripción completa

Detalles Bibliográficos
Autores principales: Cobble, Michael E, Frederich, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3277488/
https://www.ncbi.nlm.nih.gov/pubmed/22248301
http://dx.doi.org/10.1186/1475-2840-11-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3277488/
https://www.ncbi.nlm.nih.gov/pubmed/22248301
http://dx.doi.org/10.1186/1475-2840-11-6

Ejemplares similares